What to explore next?
Patient portrayal.
Individual results may vary.
FAQs
Selective serotonin reuptake inhibitors (SSRIs) are a common type of antidepressant used to treat Major Depressive Disorder (MDD) by enhancing specific serotonergic activity in the CNS.14
The mechanism of the antidepressant effect of TRINTELLIX is not fully understood, although it is thought to be related to its enhancement of serotonergic activity through inhibition of the reuptake of serotonin (5-HT).1 It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism. The contribution of these activities to TRINTELLIX's antidepressant effect has not been established.
For descriptions and symptoms of MDD, and a hypothetical patient profile, please see Diagnostic Criteria & Patient Profile.
The mean terminal half-life of TRINTELLIX is approximately 66 hours, and steady-state plasma concentrations are typically achieved within two weeks of dosing.1
Multiple drugs have the potential to interact with TRINTELLIX, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TRINTELLIX and some drugs should not be taken concomitantly as co-administration may lead to serious side effects or decreases in efficacy.1
See below for clinically important interactions with TRINTELLIX.1
NOTE: this is not an exhaustive list of TRINTELLIX drug interactions. Please see the Full Prescribing Information for further information.
Monoamine Oxidase Inhibitors (MAOIs)
Clinical Impact | The concomitant use of SSRIs and SNRIs including TRINTELLIX with MAOIs increases the risk of serotonin syndrome. |
Intervention | Concomitant use of TRINTELLIX is contraindicated:
|
Examples | selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue |
Other Serotonergic Drugs
Clinical Impact | Concomitant use of TRINTELLIX with other serotonergic drugs increases the risk of serotonin syndrome. |
Intervention | Monitor for symptoms of serotonin syndrome when TRINTELLIX is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of TRINTELLIX and/or concomitant serotonergic drugs. |
Examples | Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St. John’s Wort |
Strong Inhibitors of CYP2D6
Clinical Impact | Concomitant use of TRINTELLIX with strong CYP2D6 inhibitors increases plasma concentrations of vortioxetine. |
Intervention | Reduce TRINTELLIX dose by half when a strong CYP2D6 inhibitor is coadministered. |
Examples | bupropion, fluoxetine, paroxetine, quinidine |
Strong CYP Inducers
Clinical Impact | Concomitant use of TRINTELLIX with strong CYP inducer decreases plasma concentrations of vortioxetine. |
Intervention | Consider increasing the TRINTELLIX dose when a strong CYP inducer is coadministered. The maximum dose is not recommended to exceed three times the original dose. |
Examples | rifampin, carbamazepine, phenytoin |
Drugs that interfere with Hemostasis (antiplatlet agents and anticoagulants)
Clinical Impact | Concomitant use of TRINTELLIX with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding. |
Intervention | Inform patients of the increased risk of bleeding associated with the concomitant use of TRINTELLIX and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio. |
Examples | aspirin, clopidogrel, heparin, warfarin |
Drugs Highly Bound to Plasma Protein
Clinical Impact | TRINTELLIX is highly bound to plasma protein. The concomitant use of TRINTELLIX with another drug that is highly bound to plasma protein may increase free concentrations of TRINTELLIX or other tightly-bound drugs in plasma. |
Intervention | Monitor for adverse reactions and reduce dosage of TRINTELLIX or other protein bound drugs as warranted. |
Examples | warfarin |
The list price for TRINTELLIX is $466.35 for a 30-day prescription.* Eligible commercially insured patients may pay as little as $10 for either a 30-day or 90-day prescription with the TRINTELLIX savings card.† Savings of up to $100 per 30-day or $300 per 90-day prescription, with a maximum total savings of up to $1,300 over one year. Restrictions apply.
TRINTELLIX is available for ~85% of commercially insured patients in the US without prior authorization (PA).‡
For more information about savings or for coverage in your area, visit Savings & Support.
*As of 01/03/2023.
†See the savings card for Eligibility Requirements and Terms & Conditions.
‡Formulary data are provided by Fingertip Formulary® and are current as of September 2022. Check the patient’s individual health plan for coverage and cost information, which may change without notice.
Contact your local sales rep to request samples; if you don’t have one, you can request a rep here.
If you would like to have TRINTELLIX samples shipped to your office, please visit MySampleCloset and follow the steps below:
Please note that when a TRINTELLIX sample order is placed on the MySampleCloset website, your local Takeda representative will be notified so that they can expedite delivery by bringing them to your office personally. If the representative is unable to deliver your order, the samples will be shipped to your office.
TRINTELLIX is available in 5 mg, 10 mg, and 20 mg tablets.1
For more information, visit our Dosing page, or see Full Prescribing Information.
The recommended starting dose of TRINTELLIX is 10 mg administered orally once daily without regard to meals.1 Dosage can then be titrated to 20 mg/day, as tolerated. The efficacy and safety of doses above 20 mg/day have not been evaluated in controlled clinical trials. A dose decrease down to 5 mg/day may be considered for patients who do not tolerate higher doses.
Prior to initiating treatment with TRINTELLIX, screen patients for personal or family history of bipolar disorder, mania, or hypomania.1
Although patients can abruptly discontinue therapy with TRINTELLIX, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for one week prior to full discontinuation if possible.1
The maximum recommended dose is 10 mg/day in known CYP2D6 poor metabolizers.1
In placebo-controlled trials, some patients taking more than 10 mg/day experienced transient adverse reactions such as headache and muscle tension following abrupt discontinuation.1
For more information, visit our Dosing page, or see Full Prescribing Information.
This reflects the FDA-approved label dosage information. Neither Takeda nor Lundbeck can suggest treatment approaches or make recommendations for the management of patients.
For full information on treatment-related side effects and adverse reactions, see Safety Data, Important Safety Information, and the Full Prescribing Information.
What to explore next?
Support for
your patients
We’re here to help your eligible patients get the treatment you prescribe.
Safety profile
See how the safety profile fits in the story.
Prescription
savings for your
eligible patients
Find out about savings and support offered through tAccess by reading the Savings Card brochure.
Telling patients
about telehealth
As telehealth visits become more common, it’s important to have helpful resources for you and your patient.
Helping patients access savings info and support
Discover resources that may help your patients with savings and more.
Long-term
clinical data
Results from multiple clinical studies of TRINTELLIX.
Offering
patients once
daily dosing
Learning about dosage amounts and drug interactions.
Request a
rep visit
Connect with a TRINTELLIX representative.
Patient coverage
in your area
Find out about formulary coverage in your area for TRINTELLIX.
Patient profile
Learn more about a patient
living with MDD.
WARNING: SUICIDAL THOUGHTS & BEHAVIORS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most commonly observed adverse reactions for TRINTELLIX in 6- to 8-week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation, and vomiting.
DRUG INTERACTIONS
Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX.
PREGNANCY
Exposure to serotonergic antidepressants, including TRINTELLIX, in late pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to TRINTELLIX in the third trimester for PPHN and drug discontinuation syndrome.
TRINTELLIX is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Please click for Full Prescribing Information.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at
WARNING: SUICIDAL THOUGHTS & BEHAVIORS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most commonly observed adverse reactions for TRINTELLIX in 6- to 8-week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation, and vomiting.
DRUG INTERACTIONS
Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX.
PREGNANCY
Exposure to serotonergic antidepressants, including TRINTELLIX, in late pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to TRINTELLIX in the third trimester for PPHN and drug discontinuation syndrome.
TRINTELLIX is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Please click for Full Prescribing Information.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at